治療用重組抗體、蛋白質的全球市場:規模，佔有率，趨勢，預測(2022年～2028年)

全球治療用重組抗體、蛋白質的市場規模，由於抗體為基礎的治療藥的開發，哺乳類表現系統、微生物表現系統的發展等所促進。

本報告提供全球治療用重組抗體、蛋白質市場調查，市場概要，市場規模和預測，趨勢，成長要素，阻礙因素，各醫藥品分類、用途、地區的分析，及競爭情形等資訊。

目錄

第1章 調查目的、前提條件

• 調查目的
• 假設
• 簡稱

第2章 市場展望

• 報告的說明
  • 市場定義和範圍
• 摘要整理
  • 市場明細:各醫藥品分類
  • 市場明細:各用途
  • 市場明細:各地區
• Coherent Opportunity Map(COM)

第3章 市場動態，法規，及趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 市場趨勢
• 開發平台分析
• 醫藥品開發的課題
• 新市場進入者
• 法規情境
• PEST分析
• 波特分析

第4章 全球治療用重組抗體、蛋白質市場:各醫藥品分類(2017年～2028年)

• 簡介
• 血漿蛋白質
• 成長因素
• 融合蛋白質
• 單株抗體
• 荷爾蒙
• 酵素
• 凝血因子
• 其他

第5章 全球治療用重組抗體、蛋白質市場:各用途(2017年～2028年)

• 簡介
• 腫瘤學
• 血液學
• 免疫學
• 內分泌學
• 感染疾病
• 循環系統疾病
• 其他

第6章 全球治療用重組抗體、蛋白質市場:各地區(2017年～2028年)

• 簡介
• 北美
• 南美
• 歐洲
• 亞太地區
• 中東
• 非洲

第7章 競爭情形

• 熱圖分析
• 企業簡介
  • Abbott*
  • Amgen Inc.
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Johnson and Johnson
  • Merck &Co.
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi SA
• 分析師的見解

第8章 Section

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.

Market Dynamics

Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.

Key features of the study:

This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans

Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:

North America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

U.S.

Canada

Latin America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

GCC

Israel

Rest of Middle East

Africa Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

North Africa

South Africa

Central Africa

Company Profiles

Abbott Laboratories*

Company Overview

Product Portfolio

Key Highlights

Financial Overview

Market Strategy

Amgen Inc.

Biogen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche

Johnson and Johnson

Merck & Co.

Novo Nordisk

Pfizer, Inc.

Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Application
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Pipeline Analysis
• Drug Development Challenges
• New Market Entrants
• Regulatory Scenario
• PEST Analysis
• Porter's Analysis

4. Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Plasma Protein
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Growth Factors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Fusion Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Hormones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Enzyme
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Coagulation Factors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Hematology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Immunology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Endocrinology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Infectious Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Cardiovascular Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • South Africa
  • Central Africa
  • North Africa

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Abbott*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Amgen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Biogen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • F. Hoffmann-La Roche
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Johnson and Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Merck & Co.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Novo Nordisk
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Sanofi S.A.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
• Analyst Views

8. Section

• References
• Research Methodology
• About us and Sales Contact